Literature DB >> 30472941

Molecular Pathogenesis in Huntington's Disease.

S N Illarioshkin1, S A Klyushnikov2,3, V A Vigont4, Yu A Seliverstov2, E V Kaznacheyeva4.   

Abstract

Huntington's disease (HD) is a severe autosomal dominant neurodegenerative disorder characterized by a combination of motor, cognitive, and psychiatric symptoms, atrophy of the basal ganglia and the cerebral cortex, and inevitably progressive course resulting in death 5-20 years after manifestation of its symptoms. HD is caused by expansion of CAG repeats in the HTT gene, which leads to pathological elongation of the polyglutamine tract within the respective protein - huntingtin. In this review, we present a modern view on molecular biology of HD as a representative of the group of polyglutamine diseases, with an emphasis on conformational changes of mutant huntingtin, disturbances in its cellular processing, and proteolytic stress in degenerating neurons. Main pathogenetic mechanisms of neurodegeneration in HD are discussed in detail, such as systemic failure of transcription, mitochondrial dysfunction and suppression of energy metabolism, abnormalities of cytoskeleton and axonal transport, microglial inflammation, decrease in synthesis of brain-derived neurotrophic factor, etc.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30472941     DOI: 10.1134/S0006297918090043

Source DB:  PubMed          Journal:  Biochemistry (Mosc)        ISSN: 0006-2979            Impact factor:   2.487


  13 in total

1.  Mitofusin-2 regulates inflammation-mediated mouse neuroblastoma N2a cells dysfunction and endoplasmic reticulum stress via the Yap-Hippo pathway.

Authors:  Shu Hou; Lili Wang; Guoping Zhang
Journal:  J Physiol Sci       Date:  2019-05-27       Impact factor: 2.781

Review 2.  Exploring the role of high-mobility group box 1 (HMGB1) protein in the pathogenesis of Huntington's disease.

Authors:  Efthalia Angelopoulou; Yam Nath Paudel; Christina Piperi
Journal:  J Mol Med (Berl)       Date:  2020-02-08       Impact factor: 4.599

Review 3.  Spermatozoan Metabolism as a Non-Traditional Model for the Study of Huntington's Disease.

Authors:  Meghan Lawlor; Michal Zigo; Karl Kerns; In Ki Cho; Charles A Easley Iv; Peter Sutovsky
Journal:  Int J Mol Sci       Date:  2022-06-28       Impact factor: 6.208

Review 4.  Brain energy rescue: an emerging therapeutic concept for neurodegenerative disorders of ageing.

Authors:  Stephen C Cunnane; Mark J Millan; Eugenia Trushina; Cecilie Morland; Alessandro Prigione; Gemma Casadesus; Zane B Andrews; M Flint Beal; Linda H Bergersen; Roberta D Brinton; Suzanne de la Monte; Anne Eckert; Jenni Harvey; Ross Jeggo; Jack H Jhamandas; Oliver Kann; Clothide Mannoury la Cour; William F Martin; Gilles Mithieux; Paula I Moreira; Michael P Murphy; Klaus-Armin Nave; Tal Nuriel; Stéphane H R Oliet; Frédéric Saudou; Mark P Mattson; Russell H Swerdlow
Journal:  Nat Rev Drug Discov       Date:  2020-07-24       Impact factor: 84.694

Review 5.  Huntington's Disease-An Outlook on the Interplay of the HTT Protein, Microtubules and Actin Cytoskeletal Components.

Authors:  Aleksandra S Taran; Lilia D Shuvalova; Maria A Lagarkova; Irina B Alieva
Journal:  Cells       Date:  2020-06-22       Impact factor: 6.600

6.  Co-chaperones DNAJA1 and DNAJB6 are critical for regulation of polyglutamine aggregation.

Authors:  Claudio Rodríguez-González; Shiying Lin; Sertan Arkan; Christian Hansen
Journal:  Sci Rep       Date:  2020-05-18       Impact factor: 4.379

Review 7.  Much More Than a Scaffold: Cytoskeletal Proteins in Neurological Disorders.

Authors:  Diana C Muñoz-Lasso; Carlos Romá-Mateo; Federico V Pallardó; Pilar Gonzalez-Cabo
Journal:  Cells       Date:  2020-02-04       Impact factor: 6.600

8.  Quantification of Huntington's Disease Related Markers in the R6/2 Mouse Model.

Authors:  Estibaliz Etxeberria-Rekalde; Saioa Alzola-Aldamizetxebarria; Stefanie Flunkert; Isabella Hable; Magdalena Daurer; Joerg Neddens; Birgit Hutter-Paier
Journal:  Front Mol Neurosci       Date:  2021-01-11       Impact factor: 5.639

Review 9.  Purinergic Signaling in the Pathophysiology and Treatment of Huntington's Disease.

Authors:  Melissa Talita Wiprich; Carla Denise Bonan
Journal:  Front Neurosci       Date:  2021-07-01       Impact factor: 4.677

Review 10.  The PERK-Dependent Molecular Mechanisms as a Novel Therapeutic Target for Neurodegenerative Diseases.

Authors:  Wioletta Rozpędek-Kamińska; Natalia Siwecka; Adam Wawrzynkiewicz; Radosław Wojtczak; Dariusz Pytel; J Alan Diehl; Ireneusz Majsterek
Journal:  Int J Mol Sci       Date:  2020-03-19       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.